Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Insider Neil Gallagher Sells 4,618 Shares

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) insider Neil Gallagher sold 4,618 shares of the business’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $15.50, for a total value of $71,579.00. Following the transaction, the insider now owns 85,095 shares of the company’s stock, valued at approximately $1,318,972.50. This represents a 5.15 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Syndax Pharmaceuticals Stock Performance

Shares of NASDAQ:SNDX opened at $14.92 on Friday. The stock has a market capitalization of $1.27 billion, a price-to-earnings ratio of -4.11 and a beta of 0.90. Syndax Pharmaceuticals, Inc. has a 1-year low of $12.06 and a 1-year high of $25.34. The company has a 50 day moving average price of $13.88 and a 200 day moving average price of $17.19.

Wall Street Analysts Forecast Growth

SNDX has been the subject of several recent analyst reports. UBS Group started coverage on Syndax Pharmaceuticals in a research note on Thursday, October 24th. They issued a “buy” rating and a $37.00 price target for the company. JPMorgan Chase & Co. increased their target price on shares of Syndax Pharmaceuticals from $33.00 to $38.00 and gave the company an “overweight” rating in a research report on Thursday, November 21st. Scotiabank dropped their price target on shares of Syndax Pharmaceuticals from $18.00 to $16.00 and set a “sector perform” rating on the stock in a research report on Wednesday, January 8th. StockNews.com cut shares of Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, November 23rd. Finally, Citigroup boosted their target price on Syndax Pharmaceuticals from $37.00 to $45.00 and gave the stock a “buy” rating in a report on Tuesday, November 19th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $36.20.

Institutional Investors Weigh In On Syndax Pharmaceuticals

Several large investors have recently modified their holdings of SNDX. Nantahala Capital Management LLC lifted its holdings in shares of Syndax Pharmaceuticals by 23.7% during the fourth quarter. Nantahala Capital Management LLC now owns 560,532 shares of the company’s stock valued at $7,410,000 after purchasing an additional 107,300 shares during the last quarter. Northern Trust Corp lifted its stake in Syndax Pharmaceuticals by 7.5% during the fourth quarter. Northern Trust Corp now owns 792,750 shares of the company’s stock valued at $10,480,000 after buying an additional 55,144 shares in the last quarter. Propel Bio Management LLC boosted its holdings in shares of Syndax Pharmaceuticals by 37.5% in the fourth quarter. Propel Bio Management LLC now owns 183,259 shares of the company’s stock worth $2,423,000 after buying an additional 50,000 shares during the period. Virtus ETF Advisers LLC increased its position in shares of Syndax Pharmaceuticals by 18.6% in the fourth quarter. Virtus ETF Advisers LLC now owns 5,278 shares of the company’s stock worth $70,000 after acquiring an additional 827 shares in the last quarter. Finally, Nebula Research & Development LLC raised its holdings in shares of Syndax Pharmaceuticals by 325.6% during the fourth quarter. Nebula Research & Development LLC now owns 76,914 shares of the company’s stock valued at $1,017,000 after acquiring an additional 58,844 shares during the period.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).